Despite the growing list of safe and effective therapies for individuals with T2D, many patients struggle to achieve their glucose target and thus remain at risk for significant comorbidities. Novel unimolecular dual agonists may help address these unmet needs.
What role might novel agents play, and how can endocrinologists engage with their patients to make better therapeutic choices? To find out, and to earn continuing education credit, join us for the lunch symposium, Potential Benefits of Incretins Beyond Glycemic Control in T2D. Brought to you by Medical Learning Institute, Inc. and the Endocrine Society, this interactive symposium will be held 19.09.2022 from 13:00 – 14:00, in Heding Hall at Stockholmsmässan prior to the start of EASD 2022. During the session, experts will explain the incretin effect and the roles of GLP-1 and GIP, as well as the potential benefits of agonism of multiple receptors that affect energy homeostasis; they will also interpret the clinical implications of new and emerging data for the first-in-class dual GLP-1 and GIP agonist. Case studies will identify individuals with T2D who may benefit from earlier treatment intensification to improve overall health and delineate practical considerations to help individuals with T2D achieve optimal outcomes. Space is limited, so REGISTER TODAY!
This CE activity is intended for endocrinologists, diabetologists, and endocrinology fellows who provide care for individuals with T2D in Europe, and those who attend EASD.
After completing this CE activity, the participant should be better able to:
- Identify individuals with T2D who may benefit from earlier treatment intensification to achieve optimal glucose control and overall health in accordance with current guidelines
- Integrate practical considerations, experience, and SDM techniques to help individuals with T2D achieve and maintain weight loss for optimal outcomes
- Relate the pathophysiology of GLP-1 and GIP to the incretin effect and potential benefits of agonism of multiple receptors that affect energy homeostasis and the MOA of novel therapies
- Interpret the clinical implications of the efficacy and safety data of novel dual agonists for T2D and their potential impact on the treatment paradigm
The Xpeer, is accredited by the European Accreditation Council for Continuing Medical Education (EACCME(R)) to provide the following CME activity for medical specialists.
This course is accredited with 1 ECMEC(R) credit valid in 26 countries. Each medical specialist should claim only those credits that he/she actually spent in the educational activity. The EACCME(R) is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Union of Medical Specialists (UEMS) and the American Medical Association (AMA), physicians may convert EACCME(R) credits to an equivalent number of AMA PRA Category 1 Credit(s)™. Information on the process to convert EACCME(R) credit to AMA credit can be found at:
In support of improving patient care, this activity has been planned and implemented by Medical Learning Institute, Inc., Endocrine Society, and Xpeer. Medical Learning Institute, Inc. is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Medical Learning Institute, Inc. (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is developed with our educational partners, Endocrine Society and Xpeer.
Medical Learning Institute, Inc., Endocrine Society, and Xpeer, are committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, we require faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to policy. These disclosures will be provided to learners prior to the start of the CE activity.
Copyright © 2022 Medical Learning Institute, Inc. | All Rights Reserved.
- Unmet Needs in T2D
- Delineating the Incretin Effect and the Roles of GLP-1 and GIP
- Potential Benefits of Agonism of Multiple Receptors: Mechanism of Action of Unimolecular Dual Agonists
- Clinical Implications of Dual Agonis Efficacy and Safety Data
- Ask Me Anything
Velocity Clinical Research
Head of Clinical Research Diabetologie
St. Josef- Hospital Bochum Ruhr- University
Head, 1st Medical Department
This activity is supported by an educational grant from Lilly.
LOCATION & TIME
Mässvägen 1, 125 30 Älvsjö, Sweden
13:00 – 14:00